Therefore, Parecoxib may serve as a tool to study ELMO3 inhibition, and might be a potential candidate for the treatment of NSCLC, inhibiting tumor metastasis and preventing tumor recurrence. Here, ELMO3 is linked to non-small cell lung carcinoma.